AIMP1 and glioblastoma: We performed survival analysis based on AIMP1/2/3 mRNA expression levels in four GBM cohorts (TCGA n = 151, CGGA n = 220, REMBRANDT n = 181, and Gravendeel n = 155) and five LGG cohorts (TCGA-astrocytoma n = 193, TCGA-oligodendroglioma n = 99, CGGA-astrocytoma n = 88, REMBRANDT-oligodendroglioma n = 50, and REMBRANDT-astrocytoma n = 104).